Non-Hormonal Treatment of Osteoporosis
Restores Bone Density and Halts Bone Loss
Microcrystalline calcium hydroxyapatite is imported raw bone prepared by a special low temperature process (below 37°C) to preserve the protein content.
Each tablet contains:
Vitamin D3 (as cholecalciferol)………………..250 IU
Calcium (from MCHC and calcium citrate) ……….250 mg.
Phosphorus (from M.C.H.C.)…………………… 56 mg.
Boron (as boron aspartate)………………………750 mcg.
Other Ingredients : Gelatin capsule, vegetable lubricant
Prevention and Treatment of
Bone Loss with Hydroxyapatite
Microcrystalline Calcium Hydroxyapatite Complex (M.C.H.C.) has been used with great clinical success in the prevention and treatment of accelerated bone loss due to osteoporosis, not only to prevent and halt bone loss, but also to restore bone density.
M.C.H.C. has been shown to:
Restore bone density by promoting positive bone balance and net remineralization of bone in both axial and appendicular skeleton due to superior absorption and reduction in endosteal cortical bone resorption.
Reduce the risk of bone loss in metabolic bone diseases including osteoporosis, osteomalacia and rickets.
Reduce the rate of progression of osteoporosis resulting from aging, dietary calcium deficiency and secondary pathologies.
Produce favorable biochemical and radiological bone changes which lessen skeletal pain in patients developing osteoporosis.
Reduce the incidence of fractures and facilitate healing of fractures.
Effective Natural Therapy for Osteoporosis Patients
Osteoporosis is characterized by decreased bone density with increased susceptibility to fractures. Bone loss coincides with decreased physical activity in both sexes in later years and is vigorously aggravated by age-associated hormonal changes in women and chronic inadequate dietary intake of calcium.
However, osteoporosis is not limited to “natural” aging and dietary deficiency. Secondary pathologies can also induce bone mineral loss. Demineralization and cortical bone thinning always occur in primary biliary cirrhosis patients and osteoporosis is one of the principal complications of long–term corticosteroid treatment for respiratory problems and rheumatoid arthritis.
Calcium supplements, sodium fluoride and estrogens are the only agents whose ability to influence favorably the process of osteoporosis has been established. Of these, only calcium is without potential hazards.
Sodium fluoride improves mineralization of bone, but also induces osteomalacia. This can be counteracted by simultaneous treatment with calcium and vitamin D. Other side effects of sodium fluoride therapy include gastrointestinal intolerance and rheumatic symptoms such as transient synovitis and plantar facitis.
In comparison studies, M.C.H.C. was shown to increase serum calcium levels nearly twice as much as calcium gluconate and significantly more than ashed bone. Increased serum calcium has been shown to suppress production of parathyroid hormone and decrease bone resorption.
Boron Reduces Calcium Excretion
A 1986 study to examine the effects of boron on major mineral metabolism in postmenopausal women, showed that daily supplementation with 3 mg. of boron markedly reduced urinary excretion of calcium and magnesium. In addition, a significant increase was seen in the blood levels of both estrogen and testosterone.
Estrogen therapy has been used for postmenopausal women to suppress the resorption of bone induced by a nocturnal surge of parathyroid hormone.
All Calcium Supplements Are Not Created Equal
Several forms of calcium are found in supple-ments. The least expensive and most readily available, calcium carbonate, has the advantage of an antacid effect in the stomach, but the disadvantages of producing carbon dioxide and of interfering with digestion. Soluble calcium gluconate is similar but more palatable.
Dr. Ralph F. Shangraw, Chairman of the Department of Pharmaceutics at the University of Maryland School of Pharmacy, tested more than 80 of the calcium carbonate supplements on the market and found that the “effectiveness of over half of the tablets is questionable” due to their slow rate of disintegration and dissolution.
M.C.H.C. displays superior absorptive performance compared to other forms of calcium and has been shown, to present no hematological, biochemical or morphological signs of toxicity and no significant adverse effects have ever been reported in human use. In a comparison of microcrystalline hydroxyapatite and calcium gluconate, calcium gluconate halted bone loss but did not restore it, whereas M.C.H.C. did restore bone.
M.C.H.C. is prepared from raw bone by a special low temperature process (below 37°C) to preserve the natural protein content. The calcium thus provided is an extremely bioavailable form. In addition, the product contains trace amounts of minerals such as boron, magnesium, zinc, potassium, manganese, fluorine (as fluorapatite), silica, iron and magnesium in the natural ratios occurring in normal bone. Because of its positive effect on bone remineralization, 750 mcg. of boron has been added to each tablet.
Reduce Risk Factors — Osteoporosis Is Not Inevitable
Most adults lose minerals from bone steadily throughout their lives. In women this bone loss is accelerated for a year or two after menopause, but osteoporosis is not inevitable and some people do not lose bone.
Of course, the best cure for osteoporosis is prevention. The first step in prevention is to identify those at risk and then to eliminate as many risk factors as possible. Studies now suggest that an intake of 1,500 mg. daily after menopause and 1,000 mg. daily before menopause is necessary to maintain calcium equilibrium in women.
WARNING: This information is provided for the health professionals only. This publication and the product contained herein have not been approved or evaluated by the Food and Drug Administration. This publication, and the product contained herein are not intended to diagnose, treat, cure or prevent any disease. The product relates to nutritional support only.